Stayble receives its first approved patent for the treatment of herniated discs
Stayble Therapeutics AB ("Stayble" or "the Company") announced today that the South African patent office, as the first country, has approved the Company's patent for the treatment of herniated discs with STA363. This approval is a significant milestone for the Company and follows a previous positive international search report from European authorities. With these advancements, we see strong potential to obtain several additional national patent approvals.
The patent, titled "A composition for use in the treatment of intervertebral disc herniation," was filed at the end of 2020 and provides IP protection until 2040. Additionally, there is the possibility of applying for a five-year patent term extension in selected countries, including the USA and Japan. The patent covers the use of STA363 to treat pain arising from herniated discs.
Andreas Gerward, CEO of Stayble, comments:
"The decision by the South African patent office to approve our patent is a clear confirmation that the patent meets the requirements for patentability (novelty, inventive step, and industrial applicability). Along with previous positive statements from European authorities, including a favorable international search report, this increases our expectations of obtaining further national approvals based on our application. The patent covers the use of STA363 for treating herniated disc-related pain and provides us with the protection we need to advance our business. Strong patent protection is crucial in our industry, and this is an important first step towards global approval."
For more information
Andreas Gerward, CEO of Stayble Therapeutics AB
Mail: andreas.gerward@stayble.se
Phone: +46 730 808 397
About Stayble Therapeutics AB
Stayble is a clinical pharmaceutical company developing the injection treatment STA363 for chronic disc herniation (LDH). Stayble's vision is to offer patients a simple and effective treatment that targets the underlying cause of the patient's chronic pain and provides lasting pain relief and increased physical function. The treatment is aimed at patients who are not helped by physical therapy and painkillers and is a single injection that is expected to last a lifetime and requires minimal rehabilitation. After convincing data from previous pre-clinical and clinical studies (phase 1b and 2b) in degenerative disc disease, which show a volume reduction of the discs, the Company is currently conducting a phase 1b study for the treatment of herniated discs.
The company's Certified Adviser is Svensk Kapitalmarknadsgranskning AB.